Title : Osimertinib and anti-HER3 combination therapy engages immune dependent tumor toxicity via STING activation in trans.

Pub. Date : 2022 Mar 28

PMID : 35347108






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Thus, by engaging a tumor non-autonomous mechanism involving cGAS-STING and innate immunity, the combination of osimertinib and anti-HER3 antibodies could improve the limited therapeutic and stratification options for advanced stage lung cancer patients with mutant EGFR. osimertinib epidermal growth factor receptor Homo sapiens